SEATTLE,
Wash., April 12, 2023 /PRNewswire/ -- CTI
BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical
company focused on the development and commercialization of novel
targeted therapies for blood-related cancers, today announced that
the management team will participate in two upcoming investor
conferences in April 2023.
22nd Annual Needham Virtual Healthcare
Conference
Type: Fireside Chat
Tuesday, April 18, 2023
3:45 p.m. ET (12:45 p.m. PT)
Stifel 2023 Targeted Oncology Days (Virtual)
Type:
Corporate Presentation
Wednesday, April 26, 2023
1:00 p.m. ET (10:00 a.m. PT)
A link to the live and archived webcast may be accessed on the
CTI BioPharma website under the Investors & Media section:
Events and Presentations.
About CTI BioPharma Corp.
CTI BioPharma is a commercial biopharmaceutical company focused
on the development and commercialization of novel targeted
therapies for blood-related cancers that offer a unique benefit to
patients and their healthcare providers. CTI has one FDA-approved
product, VONJO® (pacritinib), a JAK2, ACVR1, and IRAK1 inhibitor,
that spares JAK1. VONJO is approved for the treatment of adults
with intermediate- or high-risk primary or secondary
(post-polycythemia vera or post-essential thrombocythemia)
myelofibrosis with a platelet count below 50 × 109/L. This
indication is approved under FDA accelerated approval based on
spleen volume reduction. Continued approval for this indication may
be contingent upon verification and description of clinical benefit
in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA
study of VONJO in patients with myelofibrosis and severe
thrombocytopenia as a post-marketing requirement. For more
information, please visit www.ctibiopharma.com.
VONJO® is a registered trademark of CTI BioPharma Corp.
Investor Relations and Media Contacts:
Remy Bernarda
Jenny Kobin
invest@ctibiopharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-participate-in-two-upcoming-investor-conferences-in-april-2023-301796072.html
SOURCE CTI BioPharma Corp.